JP2013017486A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013017486A5 JP2013017486A5 JP2012221023A JP2012221023A JP2013017486A5 JP 2013017486 A5 JP2013017486 A5 JP 2013017486A5 JP 2012221023 A JP2012221023 A JP 2012221023A JP 2012221023 A JP2012221023 A JP 2012221023A JP 2013017486 A5 JP2013017486 A5 JP 2013017486A5
- Authority
- JP
- Japan
- Prior art keywords
- hematopoietic stem
- protein
- conditionally immortalized
- stem cells
- proto
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims 62
- 108090000623 proteins and genes Proteins 0.000 claims 39
- 102000004169 proteins and genes Human genes 0.000 claims 38
- 108700020978 Proto-Oncogene Proteins 0.000 claims 32
- 102000052575 Proto-Oncogene Human genes 0.000 claims 32
- 210000004027 cell Anatomy 0.000 claims 29
- 238000000034 method Methods 0.000 claims 28
- 210000000130 stem cell Anatomy 0.000 claims 22
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims 18
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims 18
- 230000006907 apoptotic process Effects 0.000 claims 17
- 150000007523 nucleic acids Chemical class 0.000 claims 17
- 230000035755 proliferation Effects 0.000 claims 17
- 230000004083 survival effect Effects 0.000 claims 17
- 239000012634 fragment Substances 0.000 claims 13
- 108020004707 nucleic acids Proteins 0.000 claims 12
- 102000039446 nucleic acids Human genes 0.000 claims 12
- 230000014509 gene expression Effects 0.000 claims 11
- 102000004889 Interleukin-6 Human genes 0.000 claims 9
- 108090001005 Interleukin-6 Proteins 0.000 claims 9
- 229940100601 interleukin-6 Drugs 0.000 claims 9
- 230000004913 activation Effects 0.000 claims 8
- 108010002386 Interleukin-3 Proteins 0.000 claims 7
- 102000000646 Interleukin-3 Human genes 0.000 claims 7
- 230000010261 cell growth Effects 0.000 claims 7
- 239000003814 drug Substances 0.000 claims 7
- 102000037865 fusion proteins Human genes 0.000 claims 7
- 108020001507 fusion proteins Proteins 0.000 claims 7
- 239000003102 growth factor Substances 0.000 claims 7
- 102000051485 Bcl-2 family Human genes 0.000 claims 6
- 108700038897 Bcl-2 family Proteins 0.000 claims 6
- 101001076292 Homo sapiens Insulin-like growth factor II Proteins 0.000 claims 6
- 102100025947 Insulin-like growth factor II Human genes 0.000 claims 6
- 102000036693 Thrombopoietin Human genes 0.000 claims 6
- 108010041111 Thrombopoietin Proteins 0.000 claims 6
- 229940068935 insulin-like growth factor 2 Drugs 0.000 claims 6
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 5
- 101710149951 Protein Tat Proteins 0.000 claims 5
- 150000001875 compounds Chemical class 0.000 claims 5
- 238000012258 culturing Methods 0.000 claims 5
- 102000003971 Fibroblast Growth Factor 1 Human genes 0.000 claims 4
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 claims 4
- 238000004113 cell culture Methods 0.000 claims 4
- 229940029303 fibroblast growth factor-1 Drugs 0.000 claims 4
- 102000003951 Erythropoietin Human genes 0.000 claims 3
- 108090000394 Erythropoietin Proteins 0.000 claims 3
- 230000004069 differentiation Effects 0.000 claims 3
- 229940105423 erythropoietin Drugs 0.000 claims 3
- 230000001939 inductive effect Effects 0.000 claims 3
- 239000002609 medium Substances 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims 3
- 230000026683 transduction Effects 0.000 claims 3
- 238000010361 transduction Methods 0.000 claims 3
- 108010063104 Apoptosis Regulatory Proteins Proteins 0.000 claims 2
- 102000010565 Apoptosis Regulatory Proteins Human genes 0.000 claims 2
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 claims 2
- 102000004127 Cytokines Human genes 0.000 claims 2
- 108090000695 Cytokines Proteins 0.000 claims 2
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims 2
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims 2
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 claims 2
- 206010027476 Metastases Diseases 0.000 claims 2
- 210000004504 adult stem cell Anatomy 0.000 claims 2
- 108700000711 bcl-X Proteins 0.000 claims 2
- 102000055104 bcl-X Human genes 0.000 claims 2
- 230000009401 metastasis Effects 0.000 claims 2
- 230000001737 promoting effect Effects 0.000 claims 2
- 239000012679 serum free medium Substances 0.000 claims 2
- 230000002463 transducing effect Effects 0.000 claims 2
- -1 Bcl-w Proteins 0.000 claims 1
- 102100032528 C-type lectin domain family 11 member A Human genes 0.000 claims 1
- 101710167766 C-type lectin domain family 11 member A Proteins 0.000 claims 1
- 101001056180 Homo sapiens Induced myeloid leukemia cell differentiation protein Mcl-1 Proteins 0.000 claims 1
- 206010061598 Immunodeficiency Diseases 0.000 claims 1
- 208000029462 Immunodeficiency disease Diseases 0.000 claims 1
- 102100026539 Induced myeloid leukemia cell differentiation protein Mcl-1 Human genes 0.000 claims 1
- 101710150912 Myc protein Proteins 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000007502 anemia Diseases 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000001185 bone marrow Anatomy 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000011712 cell development Effects 0.000 claims 1
- 230000024245 cell differentiation Effects 0.000 claims 1
- 230000003915 cell function Effects 0.000 claims 1
- 230000004663 cell proliferation Effects 0.000 claims 1
- 230000007547 defect Effects 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 210000003743 erythrocyte Anatomy 0.000 claims 1
- 210000002950 fibroblast Anatomy 0.000 claims 1
- 238000003208 gene overexpression Methods 0.000 claims 1
- 230000009395 genetic defect Effects 0.000 claims 1
- 239000001963 growth medium Substances 0.000 claims 1
- 210000002865 immune cell Anatomy 0.000 claims 1
- 230000007813 immunodeficiency Effects 0.000 claims 1
- 230000001976 improved effect Effects 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000010354 integration Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 210000000581 natural killer T-cell Anatomy 0.000 claims 1
- 210000000822 natural killer cell Anatomy 0.000 claims 1
- 210000005259 peripheral blood Anatomy 0.000 claims 1
- 239000011886 peripheral blood Substances 0.000 claims 1
- 210000002826 placenta Anatomy 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US72813105P | 2005-10-18 | 2005-10-18 | |
| US60/728,131 | 2005-10-18 | ||
| US76599306P | 2006-02-06 | 2006-02-06 | |
| US60/765,993 | 2006-02-06 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008536713A Division JP2009511081A (ja) | 2005-10-18 | 2006-10-18 | 条件的に不死化された長期幹細胞およびそのような細胞を作製および使用する方法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014108137A Division JP6302356B2 (ja) | 2005-10-18 | 2014-05-26 | 条件的に不死化された長期幹細胞ならびにそのような細胞を作製する方法および使用する方法。 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013017486A JP2013017486A (ja) | 2013-01-31 |
| JP2013017486A5 true JP2013017486A5 (enExample) | 2014-05-22 |
| JP5726148B2 JP5726148B2 (ja) | 2015-05-27 |
Family
ID=37963171
Family Applications (8)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008536713A Pending JP2009511081A (ja) | 2005-10-18 | 2006-10-18 | 条件的に不死化された長期幹細胞およびそのような細胞を作製および使用する方法 |
| JP2012221023A Expired - Fee Related JP5726148B2 (ja) | 2005-10-18 | 2012-10-03 | 条件的に不死化された長期幹細胞ならびにそのような細胞を作製する方法および使用する方法。 |
| JP2014108137A Expired - Fee Related JP6302356B2 (ja) | 2005-10-18 | 2014-05-26 | 条件的に不死化された長期幹細胞ならびにそのような細胞を作製する方法および使用する方法。 |
| JP2016027812A Pending JP2016129515A (ja) | 2005-10-18 | 2016-02-17 | 条件的に不死化された長期幹細胞ならびにそのような細胞を作製する方法および使用する方法。 |
| JP2017166334A Expired - Fee Related JP6655050B2 (ja) | 2005-10-18 | 2017-08-31 | 条件的に不死化された長期幹細胞ならびにそのような細胞を作製する方法および使用する方法。 |
| JP2019006759A Expired - Fee Related JP6797221B2 (ja) | 2005-10-18 | 2019-01-18 | 条件的に不死化された長期幹細胞ならびにそのような細胞を作製する方法および使用する方法。 |
| JP2020119082A Active JP7078673B2 (ja) | 2005-10-18 | 2020-07-10 | 条件的に不死化された長期幹細胞ならびにそのような細胞を作製する方法および使用する方法。 |
| JP2022025236A Pending JP2022065146A (ja) | 2005-10-18 | 2022-02-22 | 条件的に不死化された長期幹細胞ならびにそのような細胞を作製する方法および使用する方法。 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008536713A Pending JP2009511081A (ja) | 2005-10-18 | 2006-10-18 | 条件的に不死化された長期幹細胞およびそのような細胞を作製および使用する方法 |
Family Applications After (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014108137A Expired - Fee Related JP6302356B2 (ja) | 2005-10-18 | 2014-05-26 | 条件的に不死化された長期幹細胞ならびにそのような細胞を作製する方法および使用する方法。 |
| JP2016027812A Pending JP2016129515A (ja) | 2005-10-18 | 2016-02-17 | 条件的に不死化された長期幹細胞ならびにそのような細胞を作製する方法および使用する方法。 |
| JP2017166334A Expired - Fee Related JP6655050B2 (ja) | 2005-10-18 | 2017-08-31 | 条件的に不死化された長期幹細胞ならびにそのような細胞を作製する方法および使用する方法。 |
| JP2019006759A Expired - Fee Related JP6797221B2 (ja) | 2005-10-18 | 2019-01-18 | 条件的に不死化された長期幹細胞ならびにそのような細胞を作製する方法および使用する方法。 |
| JP2020119082A Active JP7078673B2 (ja) | 2005-10-18 | 2020-07-10 | 条件的に不死化された長期幹細胞ならびにそのような細胞を作製する方法および使用する方法。 |
| JP2022025236A Pending JP2022065146A (ja) | 2005-10-18 | 2022-02-22 | 条件的に不死化された長期幹細胞ならびにそのような細胞を作製する方法および使用する方法。 |
Country Status (12)
| Country | Link |
|---|---|
| US (7) | US8883507B2 (enExample) |
| EP (1) | EP1942739B1 (enExample) |
| JP (8) | JP2009511081A (enExample) |
| KR (2) | KR101441843B1 (enExample) |
| CN (2) | CN105483088B (enExample) |
| AT (1) | ATE491022T1 (enExample) |
| AU (1) | AU2006304392B2 (enExample) |
| CA (2) | CA3065947C (enExample) |
| DE (1) | DE602006018768D1 (enExample) |
| IL (7) | IL296832A (enExample) |
| IN (1) | IN2014DN06624A (enExample) |
| WO (1) | WO2007047583A2 (enExample) |
Families Citing this family (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2006304392B2 (en) | 2005-10-18 | 2014-05-01 | National Jewish Health | Conditionally immortalized long-term stem cells and methods of making and using such cells |
| WO2007143139A1 (en) | 2006-05-31 | 2007-12-13 | The Brigham And Women's Hospital, Inc. | Abcb5 positive mesenchymal stem cells as immunomodulators |
| GB0619500D0 (en) * | 2006-10-03 | 2006-11-08 | Univ Keele | Treatment of fibrosis |
| JP2010521170A (ja) | 2007-03-13 | 2010-06-24 | ナショナル ジューイッシュ ヘルス | 抗体の生成方法 |
| KR101803099B1 (ko) | 2008-05-16 | 2017-11-30 | 타이가 바이오테크놀로지스, 인코포레이티드 | 항체 및 그 제조 방법 |
| ES2525411T3 (es) | 2008-07-21 | 2014-12-22 | Taiga Biotechnologies, Inc. | Células anucleadas diferenciadas y método para preparar las mismas |
| ES2681478T3 (es) | 2008-08-28 | 2018-09-13 | Taiga Biotechnologies, Inc. | Moduladores de MYC, métodos de uso de los mismos y métodos para identificar agentes que modulan MYC |
| US11542328B2 (en) | 2008-11-14 | 2023-01-03 | The Brigham And Women's Hospital, Inc. | Therapeutic and diagnostic methods relating to cancer stem cells |
| ES2796111T3 (es) | 2008-11-14 | 2020-11-25 | Brigham & Womens Hospital Inc | Métodos terapéuticos relacionados con células madre cancerosas |
| JP2012531894A (ja) * | 2009-06-29 | 2012-12-13 | レスコフ，イリヤ，ビー． | ヒト血液癌の非ヒト哺乳動物モデル |
| ES2664194T3 (es) * | 2009-09-15 | 2018-04-18 | The University Of Tokyo | Método novedoso para la producción de células diferenciadas |
| AU2014240253B2 (en) * | 2009-09-15 | 2017-08-03 | The University Of Tokyo | Novel Method for Producing Differentiated Cells |
| US20120321595A1 (en) * | 2009-11-09 | 2012-12-20 | The Brigham And Women's Hospital, Inc. | Treatment of heart disease |
| CN103025865A (zh) * | 2010-05-06 | 2013-04-03 | 干细胞医药有限公司 | 用于个性化医疗的干细胞库 |
| JP5861191B2 (ja) * | 2010-09-30 | 2016-02-16 | 国立大学法人 熊本大学 | ミエロイド系血液細胞の製造方法 |
| US8889630B2 (en) | 2011-12-23 | 2014-11-18 | Carlos Lopez | Method for hair regrowth using Granulocyte-Colony Stimulating Factor |
| US20130171115A1 (en) * | 2011-12-30 | 2013-07-04 | Gang Li | Cell-mediated gene therapy for cancer using mesenchymal stem cells expressing a suicide gene |
| EP2877189B1 (en) * | 2012-07-20 | 2021-01-06 | Taiga Biotechnologies, Inc. | Enhanced reconstitution and autoreconstitution of the hematopoietic compartment |
| US9801912B2 (en) | 2013-02-19 | 2017-10-31 | Va Boston Healthcare System | ABCB5(+) stem cells for treating ocular disease |
| US9365825B2 (en) | 2013-03-11 | 2016-06-14 | Taiga Biotechnologies, Inc. | Expansion of adult stem cells in vitro |
| US10272115B2 (en) * | 2013-03-11 | 2019-04-30 | Taiga Biotechnologies, Inc. | Production and use of red blood cells |
| BR112015028193B8 (pt) | 2013-05-10 | 2023-04-18 | Childrens Medical Center | Suporte para cicatrização de feridas |
| KR101638403B1 (ko) * | 2013-07-17 | 2016-07-11 | 아주대학교산학협력단 | RGMc를 유효성분으로 포함하는 줄기세포 유도용 배지 조성물 및 이를 이용한 줄기세포의 유도방법 |
| WO2015020993A2 (en) * | 2013-08-05 | 2015-02-12 | The Trustees Of The University Of Pennsylvania | RNAi COMPOSITIONS AND METHODS FOR TREATMENT OF FRIEDREICH'S ATAXIA |
| CN103509101B (zh) * | 2013-08-12 | 2016-11-02 | 中国科学院广州生物医药与健康研究院 | 一种扩增脐带血造血干细胞的细胞因子及其培养基 |
| EP3271456A1 (en) | 2015-03-18 | 2018-01-24 | The Regents of the University of California | Methods of preventing and reversing stem cell aging |
| CN106148266A (zh) * | 2015-04-20 | 2016-11-23 | 烟台赛泽生物技术有限公司 | 一种免疫细胞用培养基及该培养基的添加剂 |
| CN104928247B (zh) * | 2015-07-02 | 2018-03-23 | 广州赛莱拉干细胞科技股份有限公司 | 一种神经干细胞培养基及神经干细胞贴壁培养方法 |
| BR112018001232A2 (pt) * | 2015-07-21 | 2018-09-25 | The Children's Medical Center Corporation | pd-l1 que expressa células-tronco hematopoéticas e usos |
| AU2016318773B2 (en) * | 2015-09-09 | 2024-08-01 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Genetic engineering of macrophages for immunotherapy |
| US11534466B2 (en) | 2016-03-09 | 2022-12-27 | Aal Scientifics, Inc. | Pancreatic stem cells and uses thereof |
| CN105695511B (zh) * | 2016-04-13 | 2025-01-21 | 中国人民解放军第三军医大学 | 一种永生化毛囊干细胞系及其制备方法 |
| CN105713880A (zh) * | 2016-04-20 | 2016-06-29 | 广东艾时代生物科技有限责任公司 | 一种造血干细胞体外扩增培养的无血清培养基及其应用 |
| CN106279403B (zh) * | 2016-08-16 | 2019-06-11 | 长春市海兰深生物医学技术有限公司 | 一种检测天然肺癌相关抗体的组合物、试剂盒和方法 |
| EP4242298A2 (en) | 2016-12-02 | 2023-09-13 | Taiga Biotechnologies, Inc. | Nanoparticle formulations |
| CN106754728B (zh) * | 2016-12-30 | 2020-05-15 | 中国人民解放军总医院 | 后肾间充质细胞系及其制备方法与应用 |
| FR3068366B1 (fr) * | 2017-06-30 | 2023-11-24 | Francais Du Sang Ets | Procede de production de progeniteurs erythroides |
| US10149898B2 (en) | 2017-08-03 | 2018-12-11 | Taiga Biotechnologies, Inc. | Methods and compositions for the treatment of melanoma |
| CN111094328A (zh) * | 2017-08-03 | 2020-05-01 | 泰加生物工艺学公司 | 用于治疗癌症的方法和组合物 |
| WO2019060708A1 (en) | 2017-09-22 | 2019-03-28 | The Children's Medical Center Corporation | TREATMENT OF TYPE 1 DIABETES AND AUTOIMMUNE DISEASES OR DISORDERS |
| US12023357B2 (en) | 2017-10-13 | 2024-07-02 | Hackensack University Medical Center | Rejuvenated aged hematopoietic stem cells and methods of use |
| CN107937342B (zh) * | 2017-11-06 | 2021-07-06 | 中国人民解放军第四军医大学 | 一种通过内皮细胞来源的外泌体扩增神经干细胞的方法 |
| CN108070567A (zh) * | 2018-01-19 | 2018-05-25 | 皓昇莱生物制药有限公司 | 一种永生化的尿液来源细胞株及其构建方法 |
| KR20210005118A (ko) | 2018-04-25 | 2021-01-13 | 칠드런'즈 메디컬 센터 코포레이션 | Abcb5 리간드 및 기질 |
| WO2020074925A2 (en) * | 2018-10-12 | 2020-04-16 | Reneuron Limited | Induced pluripotent cell comprising a controllable transgene for conditional immortalisation |
| GB201902068D0 (en) * | 2019-02-14 | 2019-04-03 | Cambridge Entpr Ltd | Methods of reactivating proliferative capacity non-proliferative tissues |
| AU2020272664A1 (en) | 2019-04-08 | 2021-11-04 | Taiga Biotechnologies, Inc. | Compositions and methods for the cry opreservation of immune cells |
| AU2020274117A1 (en) | 2019-05-14 | 2021-12-02 | Taiga Biotechnologies, Inc. | Compositions and methods for treating T cell exhaustion |
| WO2021015584A1 (ko) * | 2019-07-24 | 2021-01-28 | 주식회사 에스엘바이젠 | 불사화된 줄기세포주의 제조 방법 및 이의 용도 |
| CN110622921B (zh) * | 2019-09-29 | 2021-06-15 | 江苏大学 | 阿尔茨海默病病变区FoxG1过表达小鼠模型的构建方法及应用 |
| GB202005494D0 (en) * | 2020-04-15 | 2020-05-27 | Reneuron Ltd | Induced pluripotent cell comprising a contollable transgene for conditional immortalisation |
| KR20220057859A (ko) | 2020-10-30 | 2022-05-09 | 전상수 | 펜터리 |
| JPWO2022097716A1 (enExample) | 2020-11-06 | 2022-05-12 | ||
| CN113444730A (zh) * | 2021-03-17 | 2021-09-28 | 昆明市延安医院 | 一种原发性肝细胞klotho基因转导干细胞筛选构建方法 |
| EP4365283A4 (en) * | 2021-06-30 | 2025-06-11 | National University Corporation Chiba University | Methods for improving the proliferative properties of common myeloid progenitor cells (CMP) or myelocytic progenitor cells |
| CN113583965A (zh) * | 2021-08-05 | 2021-11-02 | 大连干细胞与精准医学创新研究院 | 一种条件永生化人神经干细胞来源细胞膜纳米囊泡制剂及其制备方法和应用 |
| WO2023069882A1 (en) * | 2021-10-20 | 2023-04-27 | University Of Rochester | Method for rejuvenating glial progenitor cells and rejuvenated glial progenitor cells per se |
| EP4501338A1 (en) | 2022-03-28 | 2025-02-05 | Hiroko Science Inc. | Pharmaceutical composition containing mir-140 and method for producing same |
Family Cites Families (131)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA811368B (en) | 1980-03-24 | 1982-04-28 | Genentech Inc | Bacterial polypedtide expression employing tryptophan promoter-operator |
| JPS62501537A (ja) * | 1984-12-21 | 1987-06-25 | テクニクロン・リサ−チ・パ−トナ−ズ・ワン | リンパ球細胞を電気的に不滅化するための方法 |
| DE3531430A1 (de) | 1985-09-03 | 1987-03-05 | Biotest Pharma Gmbh | Verfahren zur gewinnung von komponenten aus einer fluessigkeit mit in raeumlich getrennten bereichen vorliegenden komponenten |
| US4963489A (en) * | 1987-04-14 | 1990-10-16 | Marrow-Tech, Inc. | Three-dimensional cell and tissue culture system |
| US4900322A (en) | 1986-09-22 | 1990-02-13 | Adams James D | Blood component pooling valve and kit |
| US5476996A (en) | 1988-06-14 | 1995-12-19 | Lidak Pharmaceuticals | Human immune system in non-human animal |
| US5399493A (en) | 1989-06-15 | 1995-03-21 | The Regents Of The University Of Michigan | Methods and compositions for the optimization of human hematopoietic progenitor cell cultures |
| US5804604A (en) | 1989-12-21 | 1998-09-08 | Biogen, Inc. | Tat-derived transport polypeptides and fusion proteins |
| US5674980A (en) * | 1989-12-21 | 1997-10-07 | Biogen Inc | Fusion protein comprising tat-derived transport moiety |
| US5849288A (en) | 1990-01-15 | 1998-12-15 | Yeda Research And Development Co. Ltd. | Method for production of monoclonal antibodies in chimeric mice or rats having xenogeneic antibody-producing cells |
| US6255458B1 (en) | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
| US5851828A (en) | 1991-03-07 | 1998-12-22 | The General Hospital Corporation | Targeted cytolysis of HIV-infected cells by chimeric CD4 receptor-bearing cells |
| IL101147A (en) | 1991-03-07 | 2004-06-20 | Gen Hospital Corp | Redirection of cellular immunity by receptor chimeras |
| US6753162B1 (en) | 1991-03-07 | 2004-06-22 | The General Hospital Corporation | Targeted cytolysis of HIV-infected cells by chimeric CD4 receptor-bearing cells |
| US5843728A (en) | 1991-03-07 | 1998-12-01 | The General Hospital Corporation | Redirection of cellular immunity by receptor chimeras |
| US5912170A (en) | 1991-03-07 | 1999-06-15 | The General Hospital Corporation | Redirection of cellular immunity by protein-tyrosine kinase chimeras |
| US6004811A (en) | 1991-03-07 | 1999-12-21 | The Massachussetts General Hospital | Redirection of cellular immunity by protein tyrosine kinase chimeras |
| AU781922B2 (en) | 1991-12-17 | 2005-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5289858A (en) | 1991-12-18 | 1994-03-01 | Abbott Laboratories | System for accommodating withdrawal of liquid from a bulk supply |
| US8211422B2 (en) | 1992-03-18 | 2012-07-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric receptor genes and cells transformed therewith |
| JP2702285B2 (ja) | 1992-08-21 | 1998-01-21 | バイオジェン，インコーポレイテッド | Ｔａｔ由来の輸送ポリペプチド |
| US5580760A (en) | 1993-02-22 | 1996-12-03 | The United States Of America As Represented By The Department Of Health And Human Services | FUSE binding protein and cDNA therefor |
| US5824837A (en) | 1993-07-22 | 1998-10-20 | Merck & Co., Inc. | Expression of human interleukin-1β in a transgenic animal |
| US5599705A (en) | 1993-11-16 | 1997-02-04 | Cameron; Robert B. | In vitro method for producing differentiated universally compatible mature human blood cells |
| WO1995023512A1 (en) | 1994-03-03 | 1995-09-08 | Alexion Pharmaceuticals, Inc. | Terminal complement inhibitor fusion genes and proteins |
| US5827642A (en) | 1994-08-31 | 1998-10-27 | Fred Hutchinson Cancer Research Center | Rapid expansion method ("REM") for in vitro propagation of T lymphocytes |
| US6713247B1 (en) * | 1996-09-03 | 2004-03-30 | Signal Pharmaceuticials, Inc. | Human CNS cell lines and methods of use therefor |
| AU734827B2 (en) | 1997-05-21 | 2001-06-21 | Board Of Trustees Of The Leland Stanford Junior University | Composition and method for enhancing transport across biological membranes |
| EP0893493A3 (de) | 1997-07-21 | 2002-12-04 | Aventis Pharma Deutschland GmbH | Genetisch veränderte Zellen und deren Verwendung in der Prophylaxe oder Therapie von Erkrankungen |
| GB9720585D0 (en) | 1997-09-26 | 1997-11-26 | Smithkline Beecham Biolog | Vaccine |
| WO1999029721A1 (en) | 1997-12-10 | 1999-06-17 | Washington University | Anti-pathogen system and methods of use thereof |
| EP1070757B1 (en) | 1998-04-08 | 2005-02-02 | Shionogi & Co., Ltd. | Methods for isolating osteoclast precursor cells and inducing the differentiation of the same into osteoclasts |
| US6835567B1 (en) * | 1998-04-14 | 2004-12-28 | Signal Pharmaceuticals, Inc. | PNS cell lines and methods of use therefor |
| US6451558B1 (en) | 1998-08-03 | 2002-09-17 | Novartis Ag | Genes in the control of hematopoiesis |
| US6913925B1 (en) * | 1998-08-12 | 2005-07-05 | Signal Pharmaceuticals Llc | Human mesencephalon cell lines and methods of use therefor |
| CA2364690A1 (en) | 1999-02-28 | 2000-10-19 | Washington University | Novel transduction molecules and methods for using same |
| AU4070500A (en) * | 1999-04-05 | 2000-10-23 | Biocrystal Limited | Assay kits and methods for immune complex-mediated activation involving shed antigens |
| ATE342275T1 (de) | 1999-04-12 | 2006-11-15 | Heart Biosystems Gmbh | Vorübergehend-immortalisierte zellen zur verwendung in gentherapie |
| US6451601B1 (en) * | 1999-04-12 | 2002-09-17 | Modex Therapeutiques, S.A. | Transiently immortalized cells for use in gene therapy |
| US6358739B1 (en) | 1999-04-12 | 2002-03-19 | Modex Therapeutiques, S.A. | Transiently immortalized cells |
| US7135287B1 (en) | 1999-10-02 | 2006-11-14 | Biosite, Inc. | Human antibodies |
| US7311920B1 (en) | 1999-10-08 | 2007-12-25 | University Of Maryland Biotechnology Institute | Virus coat protein/receptor chimeras and methods of use |
| CA2390011A1 (en) * | 1999-11-10 | 2001-05-17 | Rigel Pharmaceuticals, Inc. | Methods and compositions comprising renilla gfp |
| EP1103615A1 (en) | 1999-11-25 | 2001-05-30 | Universite De Geneve | Vectors capable of immortalizing non-dividing cells and cells immortalized with said vectors |
| US20010049393A1 (en) | 1999-12-07 | 2001-12-06 | Whitehead Institute For Biomedical Research | Methods for defining MYC target genes and uses thereof |
| WO2001087058A1 (en) | 2000-05-15 | 2001-11-22 | Sonoko Habu | Chimeric mouse having immunity constructed by using human cd34-positive cells and use thereof |
| US20020155127A1 (en) | 2000-06-02 | 2002-10-24 | Danher Wang | Genetic vaccine against human immunodeficiency virus |
| US20030072794A1 (en) | 2000-06-09 | 2003-04-17 | Teni Boulikas | Encapsulation of plasmid DNA (lipogenes™) and therapeutic agents with nuclear localization signal/fusogenic peptide conjugates into targeted liposome complexes |
| US20070248618A1 (en) | 2004-03-16 | 2007-10-25 | Cohen David I | Tat-Based vaccine Compositions and Methods of Making and Using Same |
| CA2423093C (en) | 2000-09-25 | 2013-09-17 | Valentis, Inc. | Improved system for regulation of transgene expression |
| WO2002036738A2 (en) | 2000-10-30 | 2002-05-10 | Kalobios, Inc. | Affinity maturation by competitive selection |
| ES2386884T3 (es) | 2000-11-01 | 2012-09-04 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Vectores de expresión capaces de inducir respuesta inmunomejorada y métodos para usarlos |
| US7145055B2 (en) | 2000-12-01 | 2006-12-05 | Central Institute For Experimental Animals | Method of producing a mouse suitable for the engraftment, differentiation and proliferation of heterologous cells, mouse produced by this method and use of the mouse |
| WO2002057436A2 (en) | 2001-01-19 | 2002-07-25 | Gendel Limited | Red blood cell from a transgenic animal as vehicle for polypeptide delivery |
| JP3454818B1 (ja) * | 2001-03-16 | 2003-10-06 | 直哉 小林 | 肝臓細胞の増殖方法、該方法により得られる肝臓細胞、およびその用途 |
| EP1397382B1 (en) * | 2001-05-31 | 2008-08-06 | Novartis AG | Novel estrogen receptor ligand binding domain variants and novel ligands and pharmaceutical compositions |
| JP4317940B2 (ja) | 2001-08-31 | 2009-08-19 | イミュノコア・リミテッド | 物質 |
| CN1408850A (zh) * | 2001-09-18 | 2003-04-09 | 王虹 | 人血树突状细胞永生化技术 |
| CN100506978C (zh) | 2001-09-21 | 2009-07-01 | 中国人民解放军军事医学科学院野战输血研究所 | 一种新的造血干/祖细胞的富集方法及其体外定向诱导分化 |
| GB0124391D0 (en) | 2001-10-11 | 2001-11-28 | Gene Expression Technologies L | Control of gene expression |
| JP2005508171A (ja) | 2001-11-02 | 2005-03-31 | タノックス インコーポレーテッド | Ｂ細胞悪性病変の診断及び予防に用いるためのｂ細胞リンパ腫特異抗原 |
| EP1321034A1 (en) * | 2001-12-21 | 2003-06-25 | Pfizer Products Inc. | Disruption of the phosphodieterase 10 gene |
| US7745140B2 (en) | 2002-01-03 | 2010-06-29 | The Trustees Of The University Of Pennsylvania | Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool |
| WO2003057171A2 (en) | 2002-01-03 | 2003-07-17 | The Trustees Of The University Of Pennsylvania | Activation and expansion of t-cells using an engineered multivalent signaling platform |
| WO2003068941A2 (en) | 2002-02-13 | 2003-08-21 | Duke University | Modulation of immune response by non-peptide binding stress response polypeptides |
| CN1240439C (zh) | 2002-03-28 | 2006-02-08 | 南京凯基生物科技发展有限公司 | 肿瘤基因开关药物 |
| US7211191B2 (en) | 2004-09-30 | 2007-05-01 | Thermogenesis Corp. | Blood component separation method and apparatus |
| JP2005523012A (ja) | 2002-04-16 | 2005-08-04 | デイナ−ファーバー キャンサー インスティチュート，インコーポレイテッド | 癌モデル |
| GB2387599B (en) | 2002-04-17 | 2005-08-10 | Jason Peter Brown | Methods for producing antibodies |
| CN1659187A (zh) * | 2002-05-10 | 2005-08-24 | 新世纪药品有限公司 | 融合铁蛋白在疫苗和其他方面的应用 |
| DK1506223T3 (da) * | 2002-05-16 | 2006-04-10 | Bavarian Nordic As | Fusionsprotein af regulatoriske/accessoriske HIV-proteiner |
| CA2485939C (en) * | 2002-05-29 | 2013-10-29 | Regeneron Pharmaceuticals, Inc. | Inducible eukaryotic expression system |
| DK1545204T3 (en) | 2002-09-06 | 2016-11-14 | The Government Of The Us Secretary Dept Of Health And Human Services | Immunotherapy with in vitro selected antigen-specific lymphocytes following non-myeloablative lymphodepletive chemotherapy |
| US7569664B2 (en) | 2002-10-09 | 2009-08-04 | Immunocore Limited | Single chain recombinant T cell receptors |
| PT1408114E (pt) | 2002-10-11 | 2007-04-30 | Imvision Gmbh | Moléculas modulares de transportes de antigénios ( moléculas mat ) para modulação de respostas imunitárias, correspondentes construções, processos e utilizações. |
| US20060154331A1 (en) | 2002-10-15 | 2006-07-13 | Nili Avidan | Erythrocyte differentiation factor, gene encoding same, and methods of use thereof |
| PT1558643E (pt) | 2002-11-09 | 2009-08-24 | Immunocore Ltd | Apresentação de um receptor das células t |
| WO2004050885A2 (en) | 2002-12-05 | 2004-06-17 | Imperial College Innovations Limited | Control of apoptosis using a complex of an oligonucleotide and a regulatory peptide |
| GB0304068D0 (en) | 2003-02-22 | 2003-03-26 | Avidex Ltd | Substances |
| US7482016B2 (en) | 2003-03-19 | 2009-01-27 | The J. David Gladstone Institutes | Immunogenic compositions comprising HIV-1 acetylated Tat polypeptides |
| DK1623017T3 (da) | 2003-05-08 | 2011-01-10 | Life Technologies Corp | Frembringelse og isolering af antigenspecifikke T-celler |
| WO2005014785A2 (en) | 2003-06-18 | 2005-02-17 | The George Washington University | Conditionally-immortalized hematopoietic progenitor cell lines |
| AU2004316996A1 (en) | 2003-06-20 | 2005-09-15 | The Regents Of The University Of California | Polypeptide transduction and fusogenic peptides |
| IL161903A0 (en) | 2003-07-17 | 2005-11-20 | Gamida Cell Ltd | Ex vivo progenitor and stem cell expansion for usein the treatment of disease of endodermally- deri ved organs |
| US7705049B2 (en) | 2004-01-21 | 2010-04-27 | New York University | Methods for treating non-melanoma cancers with PABA |
| JP2005232148A (ja) | 2004-02-03 | 2005-09-02 | Technion Research & Development Foundation Ltd | 神経保護剤としてプロパルギルアミンの使用 |
| WO2005114215A2 (en) | 2004-05-19 | 2005-12-01 | Avidex Ltd | Method of improving t cell receptors |
| DE602005011617D1 (de) | 2004-05-19 | 2009-01-22 | Medigene Ltd | Hochaffiner ny-eso-t-zellen-rezeptor |
| JP5563194B2 (ja) | 2004-06-29 | 2014-07-30 | イムノコア リミテッド | 改変ｔ細胞レセプターを発現する細胞 |
| US20060068469A1 (en) | 2004-08-17 | 2006-03-30 | Research Development Foundation | Bacterial vector systems |
| GB0420963D0 (en) * | 2004-09-21 | 2004-10-20 | Reneuron Ltd | Hepatocyte |
| US7767453B2 (en) * | 2004-10-20 | 2010-08-03 | Whitehead Institute For Biomedical Research | Cultured hematopoietic stem cells and method for expansion and analysis thereof |
| US8795650B2 (en) | 2004-12-09 | 2014-08-05 | The Regents Of The University Of California | Derivation of unlimited quantities of neutrophils or monocyte/dendritic cells |
| US20060156422A1 (en) | 2005-01-10 | 2006-07-13 | Medical Research Council | Methods and compositions for the generation of antibodies |
| WO2006104978A2 (en) | 2005-03-25 | 2006-10-05 | Curagen Corporation | Antibodies against the tenascin major antigens |
| EP1876894A1 (en) | 2005-04-26 | 2008-01-16 | The Board of Trustees of the University of Illinois | Nucleoside compounds and methods of use thereof |
| EP1885754B1 (en) | 2005-05-25 | 2011-02-09 | Immunocore Ltd. | T cell receptors which specifically bind to vygfvracl-hla-a24 |
| EP1928484B1 (en) | 2005-08-26 | 2010-02-24 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for treatment of headaches by administration of oxytocin |
| US20070047583A1 (en) | 2005-08-29 | 2007-03-01 | Siemens Aktiengesellschaft | Method for using a short address in a packet header |
| AU2006304392B2 (en) | 2005-10-18 | 2014-05-01 | National Jewish Health | Conditionally immortalized long-term stem cells and methods of making and using such cells |
| CA2626584A1 (en) | 2005-11-04 | 2007-05-18 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of nav1.8 gene |
| EP1792627A1 (en) | 2005-12-05 | 2007-06-06 | ImVisioN AG | Modulation of the immune response by administration of intralymphatic transduction allergen (ITAG-)-molecules |
| WO2008039818A2 (en) | 2006-09-26 | 2008-04-03 | Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Modified t cell receptors and related materials and methods |
| EP2087000A2 (en) | 2006-09-29 | 2009-08-12 | Immunocore Ltd. | T cell therapies |
| JP2010521170A (ja) | 2007-03-13 | 2010-06-24 | ナショナル ジューイッシュ ヘルス | 抗体の生成方法 |
| WO2009059304A2 (en) | 2007-11-02 | 2009-05-07 | Taiga Biotechnologies, Inc. | Compounds for treating abnormal cellular proliferation |
| ES2690554T3 (es) | 2008-03-17 | 2018-11-21 | The Scripps Research Institute | Enfoques químicos y genéticos combinados para la generación de células madre pluripotentes inducidas |
| KR101803099B1 (ko) | 2008-05-16 | 2017-11-30 | 타이가 바이오테크놀로지스, 인코포레이티드 | 항체 및 그 제조 방법 |
| US8481492B2 (en) | 2008-06-13 | 2013-07-09 | Life & Brain Gmbh | Fusion protein and use thereof |
| ES2525411T3 (es) | 2008-07-21 | 2014-12-22 | Taiga Biotechnologies, Inc. | Células anucleadas diferenciadas y método para preparar las mismas |
| ES2681478T3 (es) | 2008-08-28 | 2018-09-13 | Taiga Biotechnologies, Inc. | Moduladores de MYC, métodos de uso de los mismos y métodos para identificar agentes que modulan MYC |
| EP3031907B1 (en) | 2008-11-06 | 2021-01-06 | Indiana University Research and Technology Corporation | Materials and methods to enhance hematopoietic stem cells engraftment procedures |
| CA2743669C (en) | 2008-11-24 | 2018-10-16 | Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Fuer Gesundheit Und Umwelt (Gmbh) | High affinity t cell receptor and use thereof |
| WO2011100477A2 (en) | 2010-02-10 | 2011-08-18 | Taiga Biotechnologies, Inc. | Antibodies and processes for preparing the same |
| US20120107317A1 (en) | 2010-10-27 | 2012-05-03 | The University Of Hong Kong | Use of cytoplasmic c-myc for regulating immune responses |
| US20120244133A1 (en) | 2011-03-22 | 2012-09-27 | The United States of America, as represented by the Secretary, Department of Health and | Methods of growing tumor infiltrating lymphocytes in gas-permeable containers |
| SI2755997T1 (sl) | 2011-09-15 | 2018-11-30 | The United States of America, as represented by Secretary, Department of Health and Human Services, Office of Technology Transfer, National Institutes of Health | T-celični receptorji, ki prepoznajo HLA-A1- ali HLA-CW7-omejeni mage |
| RU2665548C2 (ru) | 2012-05-03 | 2018-08-30 | Фред Хатчинсон Кансэр Рисёч Сентер | Способ получения клеток, экспрессирующих т-клеточный рецептор |
| DE102012209673A1 (de) | 2012-06-08 | 2013-12-24 | Artcline Gmbh | Verfahren zum Herstellen einer Leukozytenpräparation und Leukozytenpräparation |
| EP2877189B1 (en) | 2012-07-20 | 2021-01-06 | Taiga Biotechnologies, Inc. | Enhanced reconstitution and autoreconstitution of the hematopoietic compartment |
| WO2014018863A1 (en) | 2012-07-27 | 2014-01-30 | The Board Of Trustees Of The University Of Illinois | Engineering t-cell receptors |
| US20140109246A1 (en) | 2012-09-24 | 2014-04-17 | The Regents Of The University Of Colorado, A Body Corporate | Methods of generating xenochimaeric mice with tumor and hematopoietic system from the same heterologous species |
| GB2508414A (en) | 2012-11-30 | 2014-06-04 | Max Delbrueck Centrum | Tumour specific T cell receptors (TCRs) |
| US20160010058A1 (en) | 2013-03-01 | 2016-01-14 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv | Methods of producing enriched populations of tumor-reactive t cells from tumor |
| EP2961416B1 (en) | 2013-03-01 | 2019-11-13 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Methods of producing enriched populations of tumor reactive t cells from peripheral blood |
| US10272115B2 (en) | 2013-03-11 | 2019-04-30 | Taiga Biotechnologies, Inc. | Production and use of red blood cells |
| US9365825B2 (en) | 2013-03-11 | 2016-06-14 | Taiga Biotechnologies, Inc. | Expansion of adult stem cells in vitro |
| CA2945393C (en) | 2014-04-24 | 2021-03-23 | Board Of Regents, The University Of Texas System | Application of induced pluripotent stem cells to generate adoptive cell therapy products |
| IL286025B2 (en) | 2014-12-24 | 2023-11-01 | Neximmune Inc | Nanoparticle preparations and immunotherapy methods |
| US10712344B2 (en) | 2016-01-15 | 2020-07-14 | Berkeley Lights, Inc. | Methods of producing patient-specific anti-cancer therapeutics and methods of treatment therefor |
| US10149898B2 (en) | 2017-08-03 | 2018-12-11 | Taiga Biotechnologies, Inc. | Methods and compositions for the treatment of melanoma |
-
2006
- 2006-10-18 AU AU2006304392A patent/AU2006304392B2/en not_active Ceased
- 2006-10-18 JP JP2008536713A patent/JP2009511081A/ja active Pending
- 2006-10-18 CN CN201510760532.XA patent/CN105483088B/zh not_active Expired - Fee Related
- 2006-10-18 DE DE602006018768T patent/DE602006018768D1/de active Active
- 2006-10-18 AT AT06826025T patent/ATE491022T1/de active
- 2006-10-18 CA CA3065947A patent/CA3065947C/en active Active
- 2006-10-18 KR KR1020137028338A patent/KR101441843B1/ko not_active Expired - Fee Related
- 2006-10-18 IN IN6624DEN2014 patent/IN2014DN06624A/en unknown
- 2006-10-18 KR KR1020087011791A patent/KR101441693B1/ko not_active Expired - Fee Related
- 2006-10-18 CN CN200680045545.8A patent/CN101330830B/zh not_active Expired - Fee Related
- 2006-10-18 IL IL296832A patent/IL296832A/en unknown
- 2006-10-18 WO PCT/US2006/040379 patent/WO2007047583A2/en not_active Ceased
- 2006-10-18 IL IL286053A patent/IL286053B2/en unknown
- 2006-10-18 EP EP06826025A patent/EP1942739B1/en active Active
- 2006-10-18 CA CA2626525A patent/CA2626525C/en active Active
- 2006-10-18 US US11/583,970 patent/US8883507B2/en active Active
-
2008
- 2008-04-17 IL IL190946A patent/IL190946A/en active IP Right Grant
-
2010
- 2010-02-05 US US12/701,383 patent/US9150831B2/en active Active
-
2012
- 2012-10-03 JP JP2012221023A patent/JP5726148B2/ja not_active Expired - Fee Related
-
2013
- 2013-01-30 IL IL224494A patent/IL224494B/en active IP Right Grant
-
2014
- 2014-05-26 JP JP2014108137A patent/JP6302356B2/ja not_active Expired - Fee Related
- 2014-10-08 US US14/509,870 patent/US9796961B2/en not_active Expired - Fee Related
-
2015
- 2015-10-02 US US14/873,296 patent/US20160040129A1/en not_active Abandoned
-
2016
- 2016-02-17 JP JP2016027812A patent/JP2016129515A/ja active Pending
-
2017
- 2017-08-31 JP JP2017166334A patent/JP6655050B2/ja not_active Expired - Fee Related
- 2017-12-24 IL IL256512A patent/IL256512B/en active IP Right Grant
-
2018
- 2018-07-23 US US16/042,904 patent/US10760055B2/en active Active
-
2019
- 2019-01-18 JP JP2019006759A patent/JP6797221B2/ja not_active Expired - Fee Related
- 2019-04-14 IL IL266009A patent/IL266009B/en active IP Right Grant
-
2020
- 2020-06-15 US US16/901,956 patent/US20200308545A1/en not_active Abandoned
- 2020-07-10 JP JP2020119082A patent/JP7078673B2/ja active Active
- 2020-11-02 IL IL278426A patent/IL278426B/en unknown
-
2022
- 2022-01-27 US US17/586,196 patent/US20220145253A1/en not_active Abandoned
- 2022-02-22 JP JP2022025236A patent/JP2022065146A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013017486A5 (enExample) | ||
| US20240417681A1 (en) | Methods and compositions for promoting survival & proliferation of endothelial cells & stimulating angiogenesis | |
| Tanigawa et al. | Selective in vitro propagation of nephron progenitors derived from embryos and pluripotent stem cells | |
| CN101330830B (zh) | 条件无限增殖化长期干细胞和制备和使用所述细胞的方法 | |
| Schaefer et al. | SOX2 and p53 expression control converges in PI3K/AKT signaling with versatile implications for stemness and cancer | |
| JP7048977B2 (ja) | コロニー形成培地及びその使用 | |
| JPWO2017221975A1 (ja) | Ｃｄ４ｃｄ８両陽性ｔ細胞の製造方法 | |
| CN108291196B (zh) | 表达ets转录因子的工程化的内皮细胞 | |
| US7427603B2 (en) | Method of enhancing proliferation and/or hematopoietic differentiation of stem cells | |
| JPWO2018143243A1 (ja) | 人工多能性幹細胞の作製方法 | |
| JP7298858B2 (ja) | 髄核細胞マスターレギュレーター転写因子を含む分化誘導剤、誘導髄核細胞の製造方法、および誘導髄核細胞の用途 | |
| Zach et al. | Production and functional characterization of murine osteoclasts differentiated from ER-Hoxb8-immortalized myeloid progenitor cells | |
| Hai‐Jiang et al. | Expansion of hematopoietic stem/progenitor cells | |
| JP7388755B2 (ja) | 髄核前駆細胞マスターレギュレーター転写因子を含む分化誘導剤、誘導髄核前駆細胞の製造方法、および誘導髄核前駆細胞の用途 | |
| US20230272348A1 (en) | Methods of generating hematopoietic cell preparations | |
| Seiler et al. | Induced pluripotent stem cells expressing elevated levels of sox-2, oct-4, and klf-4 are severely reduced in their differentiation from mesodermal to hematopoietic progenitor cells | |
| Hung et al. | Negative regulation of the differentiation of Flk2− CD34− LSK hematopoietic stem cells by EKLF/KLF1 | |
| JP6817633B2 (ja) | 造血幹細胞増幅誘導剤 | |
| Shi et al. | Spontaneous transformation of a clonal population of dermis-derived multipotent cells in culture | |
| Singh et al. | Stage-Specific Regulation of Erythropoiesis and Its Implications in Ex-Vivo RBCs Generation. | |
| KR101341558B1 (ko) | 고밀도 배양을 이용한 적혈구계 세포의 인 비트로 확장방법 | |
| JPWO2005056778A1 (ja) | 造血幹細胞の分化抑制又は増殖方法 | |
| Budagova et al. | Differentiating Induced Pluripotent Stem Cells into Natural Killer Cells for Adoptive Cell Immunotherapies—Comparative Characterization of Current Protocols | |
| KR102414138B1 (ko) | Wnt 단백질 활성 증진용 배지 조성물 | |
| Wehbe et al. | Induced Pluripotent Stem Cells to Model Juvenile Myelomonocytic Leukemia: New Perspectives for Preclinical Research. Cells 2021, 10, 2335 |